ADJUSTING FOR TREATMENT SWITCHING IN THE RELAPSING-REMITTING MULTIPLE SCLEROSIS CLARITY TRIAL AND THE CLARITY EXTENSION STUDY

被引：0
|
作者：
Gorrod, Bell H. [1 ]
Latimer, N. [1 ]
Damian, D. [2 ]
Hettle, R. [3 ]
Harty, G. T. [4 ]
Wong, S. L. [2 ]
机构：
[1] Univ Sheffield, Sheffield, S Yorkshire, England
[2] EMD Serono Inc, Billerica, MA USA
[3] PAREXEL Int, London, England
[4] Merck Serono, London, England
来源：
VALUE IN HEALTH | 2017年 / 20卷 / 09期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PND6
引用
收藏
页码：A718 / A718
页数：1
相关论文
共 50 条
  • [1] Impact of Nonrandomized Dropout on Treatment Switching Adjustment in the Relapsing-Remitting Multiple Sclerosis CLARITY Trial and the CLARITY Extension Study
    Gorrod, Helen Bell
    Latimer, Nicholas R.
    Damian, Doris
    Hettle, Robert
    Harty, Gerard T.
    Wong, Schiffon L.
    VALUE IN HEALTH, 2019, 22 (07) : 772 - 776
  • [2] IMPACT OF NON-RANDOMISED DROP-OUT ON TREATMENT SWITCHING ADJUSTMENT IN THE RELAPSING-REMITTING MULTIPLE SCLEROSIS CLARITY TRIAL AND THE CLARITY EXTENSION STUDY
    Gorrod, Bell H.
    Latimer, N.
    Damian, D.
    Hettle, R.
    Harty, G. T.
    Wong, S. L.
    VALUE IN HEALTH, 2017, 20 (09) : A769 - A769
  • [3] Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
    Helen Bell Gorrod
    Nicholas R. Latimer
    Doris Damian
    Robert Hettle
    Gerard T. Harty
    Schiffon L. Wong
    Advances in Therapy, 2020, 37 : 225 - 239
  • [4] Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods
    Gorrod, Helen Bell
    Latimer, Nicholas R.
    Damian, Doris
    Hettle, Robert
    Harty, Gerard T.
    Wong, Schiffon L.
    ADVANCES IN THERAPY, 2020, 37 (01) : 225 - 239
  • [5] Safety and efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis: Results from the randomized extension trial of the CLARITY study
    Giovannoni, Gavin
    Sorensen, Per Soelberg
    Cook, Stuart
    Rammohan, Kottil
    Rieckmann, Peter
    Comi, Giancarlo
    Dangond, Fernando
    Adeniji, Abidemi K.
    Vermersch, Patrick
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (12) : 1594 - 1604
  • [6] Efficacy of cladribine tablets in patients with relapsing-remitting multiple sclerosis (RRMS) in the 120-week extension to the CLARITY study
    Giovannoni, Gavin
    Comi, Giancarlo
    Cook, Stuart
    Rieckmann, Peter
    Rammohan, Kottil
    Soelberg-Soerensen, Per
    Vermersch, Patrick
    Martin, Emily
    Dangond, Fernando
    MULTIPLE SCLEROSIS JOURNAL, 2018, 24 (02) : NP6 - NP7
  • [7] Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension
    Soelberg-Sorensen, Per
    Dangond, Fernando
    Hicking, Christine
    Giovannoni, Gavin
    NEUROLOGY, 2017, 88
  • [8] Innate immune cell counts in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY extension
    Soelberg-Sorensen, P.
    Dangond, F.
    Hicking, C.
    Giovannoni, G.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 598 - 599
  • [9] Absolute lymphocyte count recovery in patients with relapsing-remitting multiple sclerosis (RRMS) treated with cladribine tablets 3.5 mg/kg in CLARITY and CLARITY Extension
    Soelberg-Sorensen, Per
    Dangond, Fernando
    Hicking, Christine
    Giovannoni, Gavin
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 (13) : NP12 - NP12
  • [10] Oral Cladribrine Treatment Reduces Brain Atrophy Rates in Relapsing-Remitting Multiple Sclerosis: Exploratory Analysis of the CLARITY Study
    De Stefano, Nicola
    Giorgio, Antonio
    De Leucio, Alessandro
    Hamlett, Anthony
    Scaramozza, Matthew
    Stubinski, Bettina
    NEUROLOGY, 2013, 80
12345